Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a

Journal of Immunology

Volumn 164, Issue 7, 2000, Pages 3783-3789

  Petering, Holger ^a   Köhl, Jörg ^a   Weyergraf, Ansgar ^a   Dulkys, Yasmin ^a   Kimmig, Daniela ^a   Smolarski, Regina ^a   Kapp, Alexander ^a   Elsner, Jörn ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; CALCIUM ION; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; COMPLEMENT ACTIVATION; DRUG POTENCY; EOSINOPHIL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NORMAL HUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RESPIRATORY BURST; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

EID: 0343183114     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.7.3783     Document Type: Article

References (45)

1. Ember, J. A., M. A. Jagels, and T. E. Hugli. 1998. Characterization of complement anaphylatoxins and their biologic responses. In The Human Complement System in Health and Disease. J. E. Volanakis and M. M. Frank, eds. Marcel Dekker, New York, p. 241.
2. Köhl, J., and D. Bitter-Suermann. 1993. Anaphylatoxins. In Complement in Health and Disease, Second Ed. K. Whaley, M. Loos, and J. M. Weiler, eds. Kluwer Academic Publishers, Dordrecht, p. 295.
3. Ames, R. S., Y. Li, H. M. Sarau, P. Nuthulaganti, J. J. Foley, C. Ellis, Z. Zeng, K. Su, A. J. Jurewicz, R. P. Hertzberg, et al. 1996. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J. Biol. Chem. 271:20231.
4. Crass, T., U. Raffetseder, U. Martin, M. Grove, A. Klos, J. Köhl, and W. Bautsch. 1996. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur. J. Immunol. 26:1944.
5. Roglic, A., E. R. Prossnitz, S. L. Cavanagh, Z. Pan, A. Zou, and R. D. Ye. 1996. cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure. Biochim. Biophys. Acta 1305:39.
6. Legler, D. F., M. Loetscher, S. A. Jones, C. A. Dahinden, M. Arock, and B. Moser. 1996. Expression of high- and low-affinity receptors for C3a on the human mast cell line, HMC-1. Eur. J. Immunol. 26:753.
7. Hartmann, K., B. M. Henz, S. Krüger-Krasagakes, J. Köhl, R. Burger, S. Guhl, I. Haase, U. Lippert, and T. Zuberbier. 1997. C3a and C5a stimulate chemotaxis of human mast cells. Blood 89:2863.
8. Nilsson, G., M. Johnell, C.H. Hammer, H. L. Tiffany, K. Nilsson, D. D. Metcalfe, A. Siegbahn, and P.M. Murphy. 1996. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J. Immunol. 157:1693.
9. Martin, U., D. Bock, L. Arseniev, M. A. Tornetta, R. S. Ames, W. Bautsch. J. Köhl, A. Ganser, and A. Klos. 1997. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J. Exp. Med. 186:199.
10. Elsner, J., M. Oppermann, W. Czech, and A. Kapp. 1994. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 83:3324.
11. Bischoff, S. C., A. L. de Weck, and C. Dahinden. 1990. Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils reponsive to low concentrations of complement component. Proc. Natl. Acad. Sci. USA 87:6813.
12. Kretzschmar, T., A. Jeromin, C. Gietz, W. Bautsch, A. Klos, J. Köhl, G. Rechkemmer, and D. Bitter-Suermann. 1993. Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a. Eur. J. Immunol. 23:558.
13. Hugli, T. E., and B. W. Erickson. 1977. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin. Proc. Natl. Acad. Sci. USA 74:1826.
14. Gerardy-Schahn, R., D. Ambrosius, D. Saunders, M. Casaretto, C. Mittler, G. Karwarth, S. Görgen, and D. Bitter-Suermann. 1989. Characterization of C3a receptor-proteins on guinea pig platelets and human polymorphnuclear leukocytes. Eur. J. Immunol. 19:1095.
15. Caporale, L. H., P. S. Tippett, B. W. Erickson, and T. E. Hugli. 1980. The active site of C3a anaphylatoxin. J. Biol. Chem. 255:10758.
16. Hugli, T. E. 1990. Structure and function of C3a anaphylatoxin. Curr. Top. Microbiol. Immunol. 153:181.
17. Köhl, J., M. Casaretto, M. Gier, G. Karwath, C. Gietz, W. Bautsch, D. Saunders, and D. Bitter-Suermann. 1990. Reevaluation of the C3a active site using short synthetic C3a analog. Eur. J. Immunol. 20:1463.
18. Elsner, J., R. Höchstetter, K. Spiekermann, and A. Kapp. 1996. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 88:4684.
19. Elsner, J., M. Oppermann, W. Czech. G. Dobos, E. Schöpf, J. Norgauer, and A. Kapp. 1994. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur. J. Immunol. 24:518.
20. Schwenk, U., and J. M. Schröder. 1995. 5-oxo-eicosanoids are potent eosinophil chemotactic factors: functional characterization and structural requirements. J. Biol. Chem. 270:15029.
21. Schwenk, U., E. Morita, R. Engel, and J. M. Schröder. 1992. Identification of 5-oxo-15-hydroxy-6,8,11,13-eicosatetraenoic acid as a novel and potent human eosinophil chemotactic eicosanoid. J. Biol. Chem. 267:12482.
22. Kapp, A., G. Zeck Kapp, W. Czech, and E. Schöpf. 1994. The chemokine RANTES is more than a chemoattractant: characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF. J. Invest. Dermatol. 102:906.
23. Petering, H., R. Höchstetter, D. Kimmig, R. Smolarski, A. Kapp, and J. Elsner. 1998. Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J. Immunol. 160:555.
24. Elsner, J., R. Höchstetter, D. Kimmig, and A. Kapp. 1996. Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur. J. Immunol. 26:1919.
25. Zeck Kapp, G., C. Kroegel, U. N. Riede, and A. Kapp. 1995. Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. Allergy 50:34.
26. Daffern, P. J., P. H. Pfeifer, J. A. Ember, and T. E. Hugli. 1995. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J. Exp. Med. 181:2119.
27. Coyle, A. J., S. Ackermann, R. Burch, D. Proud, and C. G. Irvin. 1995. Human eosinophil granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J. Clin. Invest. 95:1735.
28. Ambrosius, D., M. Casaretto, R. Gerardy-Schahn, D. Saunders, D. Brandenburg, and H. Zahn. 1989. Peptide analogues of the anaphylatoxin C3a: syntheses and properties. Biol. Chem. Hoppe Seyler 370:217.
29. Hawlisch, H., R. Frank, M. Hennecke, M. Baensch, B. Sohns, L. Arseniev, W. Bautsch, A. Kola, A. Klos, and J. Köhl. 1998. Site-directed C3a receptor antibodies from phage display libraries. J. Immunol. 160:2947.
30. 2+ measurement. J. Biol. Chem. 262:6308.
31. Elsner, J., S. Dichmann, G. J. Dobos, and A. Kapp. 1996. Actin polymerization in human eosinophils, unlike human neutrophils, depends on intracellular calcium mobilization. J. Cell Physiol. 167:548.
32. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260: 3440.
33. Kola, A., A. Klos, W. Bautsch, T. Kretzschmar, and J. Köhl. 1992. Functional activities of synthetic anaphylatoxic peptides in widely used biological assays. Clin. Exp. Immunol. 88:368.
34. Kapp, A. 1993. The role of eosinophils in the pathogenesis of atopic dermatitis -eosinophil granule proteins as markers of disease activity. Allergy 48:1.
35. Kapp, A. 1995. Atopic dermatitis-the skin manifestation of atopy. Clin. Exp. Allergy 25:210.
36. Meurer, R., G. V. Riper, W. Feeney, P. Cunningham, D. Hora, M. S. Springer, D. E. MacIntyre, and H. Rosen. 1993. Formation of eosinophilic and monocyte intradermal inflammatory sites in the dog by injection of human RANTES but not human monocytes chemoattractant protein 1, human macrophage inflammatory protein 1, or human interleukin 8. J. Exp. Med. 178:1913.
37. Costa, J. J., P. F. Weller, and S. J. Galli. 1997. The cells of the allergic response: mast cells, basophils, and eosinophils. J. Am. Med. Assoc. 278:1815.
38. Baggiolini, M. 1998. Chemokines and leukocyte traffic. Nature 392:565.
39. Takafuji, S., K. Tadokoro, K. Ito, and C. A. Dahinden. 1994. Degranulation from human eosinophils stimulated with C3a and C5a. Int. Arch. Allergy Immunol. 104(Suppl. 1):27.
40. 125I-C3a binding. Biochemistry 31:11274.
41. Settmacher, B., D. Bock, H. Saad, S. Gärtner, C. Reinheimer, J. Köhl, W. Bautsch, and A. Klos. 1999. Modulation of C3a activity: internalization of the human C3a receptor and its inhibition by C5a. J. Immunol. 15:162.
42. Kretzschmar, T., M. Pohl, M. Casaretto, M. Przewosny, W. Bautsch, A. Klos, D. Saunders, and J. Köhl. 1992. Synthetic peptides as antagonists of the anaphylatoxin C3a. Eur. J. Biochem. 210:185.
43. Gerardy-Schahn, R., D. Ambrosius, M. Casaretto, J. Grotzinger, D. Saunders, A. Wollmer, D. Brandenburg, and D. Bitter-Suermann. 1988. Design and biological activity of a new generation of synthetic C3a analogues by combination of peptidic and non-peptidic elements. Biochem. J. 255:209.
44. Federwisch, M., M. Casaretto, R. Gerardy-Schahn, D. Bitter-Suermann, and A. Wollmer. 1992. Enhanced biopotency of synthetic C3a analogues by membrane binding: a fluorescence anisotropy decay study. Biophys. Chem. 44:151.
45. Ember, J. A., N. L. Johansen, and T. E. Hugli. 1991. Designing synthetic super-agonists of C3a anaphylatoxin. Biochemistry 30:3603.